PortfoliosLab logo
Alembic Pharmaceuticals Limited (APLLTD.NS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

Highlights

Market Cap

₹177.05B

EPS (TTM)

₹29.68

PE Ratio

30.35

Total Revenue (TTM)

₹66.72B

Gross Profit (TTM)

₹44.30B

EBITDA (TTM)

₹7.79B

Year Range

₹725.20 - ₹1,303.90

Target Price

₹1,015.18

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart


Loading data...

Returns By Period

Alembic Pharmaceuticals Limited (APLLTD.NS) returned -15.52% year-to-date (YTD) and -9.03% over the past 12 months. Over the past 10 years, APLLTD.NS returned 7.78% annually, underperforming the S&P 500 benchmark at 10.46%.


APLLTD.NS

YTD

-15.52%

1M

7.19%

6M

-13.24%

1Y

-9.03%

5Y*

4.41%

10Y*

7.78%

^GSPC (Benchmark)

YTD

-3.77%

1M

7.44%

6M

-5.60%

1Y

8.37%

5Y*

14.12%

10Y*

10.46%

*Annualized

Monthly Returns

The table below presents the monthly returns of APLLTD.NS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025-13.70%-19.18%25.03%-5.83%2.88%-15.52%
202426.48%6.16%-3.42%1.50%-7.65%-5.04%36.08%-10.21%13.82%-6.36%-3.25%-2.38%41.99%
2023-6.05%-5.01%-2.92%12.05%-1.73%16.44%23.03%0.30%1.00%-9.10%4.59%1.82%34.02%
2022-5.63%-4.16%2.25%5.33%-6.29%-0.51%-3.60%-6.24%-6.72%-9.02%8.09%-3.65%-27.46%
2021-7.84%-3.35%4.80%2.15%-3.51%3.48%-18.83%-4.57%5.02%-1.51%3.80%-0.60%-21.29%
202010.40%-0.12%-14.75%39.17%17.17%4.78%7.92%-4.36%-0.43%2.83%3.47%3.57%81.90%
2019-1.01%-6.52%-6.14%6.98%-7.03%-1.80%4.07%-4.96%2.31%7.98%0.34%3.52%-3.73%
20186.88%-2.53%-0.80%-2.61%-19.95%17.57%12.24%7.11%4.90%-5.10%3.44%-2.87%13.90%
2017-5.86%3.53%8.18%-2.41%-12.31%-5.73%5.60%-2.09%-2.53%-0.28%2.56%2.50%-10.14%
2016-11.29%0.10%-3.18%0.69%-11.61%7.75%10.14%0.14%4.18%3.14%-1.99%-10.09%-13.91%
20155.60%-12.62%10.68%4.12%16.63%20.09%7.60%0.68%-4.38%-0.69%2.04%0.48%57.08%
20145.40%20.36%6.44%4.54%-17.28%8.01%31.94%6.64%11.68%-1.23%2.78%5.79%112.84%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of APLLTD.NS is 36, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of APLLTD.NS is 3636
Overall Rank
The Sharpe Ratio Rank of APLLTD.NS is 3939
Sharpe Ratio Rank
The Sortino Ratio Rank of APLLTD.NS is 3232
Sortino Ratio Rank
The Omega Ratio Rank of APLLTD.NS is 3333
Omega Ratio Rank
The Calmar Ratio Rank of APLLTD.NS is 3535
Calmar Ratio Rank
The Martin Ratio Rank of APLLTD.NS is 3939
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Alembic Pharmaceuticals Limited (APLLTD.NS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


The Sharpe ratio helps investors understand how much return they're getting for the level of risk taken. A higher Sharpe ratio indicates better risk-adjusted performance, meaning more reward for each unit of risk.

Alembic Pharmaceuticals Limited Sharpe ratios as of May 10, 2025 (values are recalculated daily):

  • 1-Year: -0.23
  • 5-Year: 0.14
  • 10-Year: 0.24
  • All Time: 0.73

These values reflect how efficiently the investment has delivered returns relative to its volatility over different time periods. All figures are annualized and based on daily total returns (including price changes and dividends).

The chart below shows the rolling Sharpe ratio of Alembic Pharmaceuticals Limited compared to the selected benchmark. This view highlights how the investment's risk-adjusted performance has changed over time. For deeper analysis or to customize the calculation, use the Sharpe ratio tool.


Loading data...

Dividends

Dividend History

Alembic Pharmaceuticals Limited provided a 1.22% dividend yield over the last twelve months, with an annual payout of ₹11.00 per share.


0.50%1.00%1.50%₹0.00₹2.00₹4.00₹6.00₹8.00₹10.00₹12.00₹14.0020142015201620172018201920202021202220232024
Dividends
Dividend Yield
PeriodTTM20242023202220212020201920182017201620152014
Dividend₹11.00₹11.00₹8.00₹10.00₹14.00₹3.00₹5.50₹4.00₹4.00₹4.00₹3.50₹3.00

Dividend yield

1.22%1.03%1.05%1.75%1.75%0.29%0.96%0.67%0.75%0.67%0.50%0.67%

Monthly Dividends

The table displays the monthly dividend distributions for Alembic Pharmaceuticals Limited. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2025₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00
2024₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹11.00₹0.00₹0.00₹0.00₹0.00₹0.00₹11.00
2023₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹8.00₹0.00₹0.00₹0.00₹0.00₹0.00₹8.00
2022₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹10.00₹0.00₹0.00₹0.00₹0.00₹10.00
2021₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹14.00₹0.00₹0.00₹0.00₹0.00₹0.00₹14.00
2020₹0.00₹0.00₹3.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00
2019₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹5.50₹0.00₹0.00₹0.00₹0.00₹0.00₹5.50
2018₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00
2017₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00
2016₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00₹0.00₹0.00₹0.00₹0.00₹0.00₹4.00
2015₹0.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.50₹0.00₹0.00₹0.00₹0.00₹0.00₹3.50
2014₹3.00₹0.00₹0.00₹0.00₹0.00₹0.00₹3.00

Dividend Yield & Payout


Dividend Yield

Alembic Pharmaceuticals Limited has a dividend yield of 1.22%, which signifies it pays a smaller percentage of its stock price in dividends to its shareholders compared to other companies in the market.

Payout Ratio

Alembic Pharmaceuticals Limited has a payout ratio of 37.97%, which is quite average when compared to the overall market. This suggests that Alembic Pharmaceuticals Limited strikes a balance between reinvesting profits for growth and paying dividends to shareholders.

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading data...

Worst Drawdowns

The table below displays the maximum drawdowns of the Alembic Pharmaceuticals Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Alembic Pharmaceuticals Limited was 57.14%, occurring on Mar 29, 2023. Recovery took 317 trading sessions.

The current Alembic Pharmaceuticals Limited drawdown is 27.81%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-57.14%Dec 18, 2020566Mar 29, 2023317Jul 16, 2024883
-45.05%Jul 17, 2015712Jun 5, 2018460Apr 24, 20201172
-40.4%Sep 12, 2024119Feb 28, 2025
-27.58%Nov 9, 201137Jan 2, 201264Apr 2, 2012101
-23.65%Apr 28, 201415May 19, 201434Jul 4, 201449

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading data...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Alembic Pharmaceuticals Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Earnings Per Share

The chart presents the Earnings Per Share (EPS) performance of Alembic Pharmaceuticals Limited, comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 11.5% positive surprise.


0.005.0010.0015.0020212022202320242025
7.98
7.16
Actual
Estimate

Valuation

The Valuation section provides an overview of how Alembic Pharmaceuticals Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for APLLTD.NS, comparing it with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, APLLTD.NS has a P/E ratio of 30.3. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for APLLTD.NS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, APLLTD.NS has a P/S ratio of 2.8. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for APLLTD.NS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, APLLTD.NS has a P/B value of 3.4. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items